

Author's Accepted Manuscript

Detection of High-Grade Prostate Cancer among PLCO Participants Using a Prespecified Four Kallikrein Marker Panel

Eric H. Kim , Gerald L. Andriole , E. David Crawford , Daniel D. Sjoberg , Melissa Assel , Andrew J. Vickers , Hans Lilja



PII: S0022-5347(16)31633-0
DOI: [10.1016/j.juro.2016.10.089](https://doi.org/10.1016/j.juro.2016.10.089)
Reference: JURO 14139

To appear in: *The Journal of Urology*

Please cite this article as: Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H, Detection of High-Grade Prostate Cancer among PLCO Participants Using a Prespecified Four Kallikrein Marker Panel, *The Journal of Urology*® (2016), doi: 10.1016/j.juro.2016.10.089.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

Detection of High-Grade Prostate Cancer among PLCO Participants Using a Prespecified Four Kallikrein Marker Panel

Eric H. Kim, MD¹, Gerald L. Andriole, MD¹, E. David Crawford, MD², Daniel D. Sjoberg, MSc³,
Melissa Assel, MS³, Andrew J. Vickers, DPhil³, and Hans Lilja, MD, PhD⁴

Corresponding author:

Hans Lilja, MD, PhD
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065, USA
Phone: 1-212-639-6982
Fax: 1-646-422-2379
E-mail: liljah@mskcc.org

Affiliations:

1. Division of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, MO
2. Division of Urology, Department of Surgery, University of Colorado, Aurora, CO
3. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4. Departments of Laboratory Medicine (Clinical Chemistry Service), Surgery (Urology Service), and Medicine (Genitourinary Oncology Service), Memorial Sloan Kettering Cancer Center, New York, NY; Nuffield Department of Surgical Sciences, University of Oxford, UK; Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden

Source of Funding: R01-CA160816 from NCI to Dr. Lilja and Dr. Vickers, funds from David H. Koch provided through the Prostate Cancer Foundation, the Sidney Kimmel Center for Prostate and Urologic Cancers, P50-CA92629 SPORE grant from the National Cancer Institute to Dr. H Scher, the P30-CA008748 NIH/NCI Cancer Center Support Grant to MSKCC, Swedish Cancer Society project number 14-0722 to Dr. Lilja, the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Program in UK, and contracts from the NCI to PLCO investigators.

Disclosures: Dr. Lilja holds patents for free PSA, hK2, and intact PSA assays, and is named, along with Dr. Vickers, on a patent application for a statistical method to detect prostate cancer, which is commercialized by OPKO Health. Drs. Vickers and Lilja receive royalties from any sales of the test. Dr. Lilja owns stock in OPKO and Dr. Vickers is on the advisory board of OPKO Health and has OPKO stock options. Dr. Vickers has a consulting or advisory role in Genome DX and Genomic Health. Dr. Lilja served on an advisory panel for Roche Diagnostics during 2014, and an immediate family member of Dr. Lilja is an employee at Ferring Pharmaceuticals. Dr. Andriole is a consultant for Augmenix and Tolmar Pharmaceuticals; clinical investigator for Blue Earth Diagnostics, Medivation, Progenics, and Traxxsson.

Role of the for-profit health care companies in the writing of the manuscript: None.

Key Words: prostate cancer, screening, prostate-specific antigen, biopsy

Abstract word count: 243/250

Manuscript word count: 2409/2500

Tables and Figures: 7/10

Download English Version:

<https://daneshyari.com/en/article/5687350>

Download Persian Version:

<https://daneshyari.com/article/5687350>

[Daneshyari.com](https://daneshyari.com)